



Cancer in Manitoba

DEPARTMENT OF EPIDEMIOLOGY & CANCER REGISTRY

2013

Annual Statistical Report



Department of Epidemiology and Cancer Registry

Table of Contents

Report from the Managers	2
Introduction to the Data	4
Manitoba's Cancer Profile	5
Facts & Figures	5
Most Common Cancers, 2013	5
Cancer Incidence by Site	6
Manitoba Cancer Rates by Regional Health Authority (Incidence)	7
Cancer Incidence—Cases & Rates by Site	8
Tumour Staging by Site	10
Deaths by Underlying Cause in Manitoba (Mortality)	13
Research: 2013 Publications	14
Appendix 1	
International Classification Of Disease for Oncology, 3rd Edition	16
Department Staff Listing	17

Vision

Through engaged partnerships, effective research, and knowledge exchange, generate relevant information on all essential facets of cancer control including prevention, screening, early detection, treatment and palliation.

Mission

To enhance the development and evaluation of a cancer control strategy by collecting data, and conducting surveillance and research across the spectrum of cancer control in Manitoba.

Department of Epidemiology and Cancer Registry

2013 Report from the Managers

The Department of Epidemiology and Cancer Registry continues its dedication to the advancement of cancer control initiatives and works diligently to provide high quality cancer information. The department continues to increase the number and complexity of variables captured in the Registry as well as providing epidemiological support to CancerCare Manitoba (CCMB) administrators, clinicians, researchers, program planners and the CancerCare Manitoba Foundation (CCMF).

Every year there is an increase in the number of projects and initiatives matched with an expectation of Departmental support. The Department is engaging with CCMB and our stakeholders to best meet the growing demand and need for data.

Data Requests

YEAR	PROGRAM PLANNING	SURVEILLANCE / EDUCATIONAL	RESEARCH	TOTAL
2009	30	15	31	76
2010	29	25	38	92
2011	17	28	64	109
2012	35	23	45	103
2013	17	26	63	106

2013 initiatives and ongoing work include:

- **Data Quality**

The Manitoba Cancer Registry has submitted 2012 data to the North American Association of Central Cancer Registries for certification. The Registry has held gold certification since 2006.

- **Staging**

Recognized as a leader in capturing stage amongst North American cancer registries, the Registry has stage at diagnosis information on cancer cases diagnosed from 2004 forward.

- **Prevention**

The Department has engaged in several projects to help determine how to reduce the risk of Manitobans getting cancer:

- The Youth Health Survey (YHS) is a collaborative project to determine youth behavioural risk factors. The Epidemiology Unit led this massive initiative (65,000 students) and provided individual reports to schools, RHAs and government departments.
- Responding to the ongoing need for public education on sun/UV safety, the Unit has engaged in outreach activities supported by CCMF.
- Due to the lack of a specific prevention unit, the Virtual Prevention Unit was created to answer the recognized need for organized and collaborative cancer prevention initiatives between CCMB departments.

- **Clinical Epidemiology**

The Department engages with CCMB clinicians and others to support research and determine clinical outcomes by:

- Dedicating cancer registrars and providing ongoing epidemiological collaboration with physicians and specific disease site groups.
- Expansion of coding to include clinical data for outcomes evaluation with disease site groups and developing and maintaining clinical databases for clinician research.
- Providing support to clinicians, students and staff throughout the research process.

- **IN SIXTY**

This major provincial initiative aims to reduce the wait times from suspicion of cancer to treatment. The Department is supporting multiple initiatives to improve the cancer patient journey.

- **System Performance**


The Department continues its work with the Canadian Partnership Against Cancer by building and updating a number of indicators with more recent data and introducing several new ones for prevention, screening, treatment and long-term outcomes.

The Department is proud of its ability to provide key knowledge, data collection support, and analytical expertise. Our dedicated team of highly skilled experts must stay abreast of current methods with ongoing continued education. We are committed to supporting population-based research which contributes to the development and evaluation of the Manitoba cancer control strategy.



Dr. Donna Turner

PROVINCIAL DIRECTOR, POPULATION ONCOLOGY
INTERIM MANAGER, EPIDEMIOLOGY UNIT
CancerCare Manitoba



Gail Noonan

MANAGER, MANITOBA CANCER REGISTRY
CancerCare Manitoba

Introduction to the Data

The Manitoba Cancer Registry is an essential tool for evidence-based, data-driven decision making that has an immense impact on treatment and research. This year's report is based on the following information.

NOTE: All statistics in the body of this report only include Manitoba residents.

Manitoba Cancer Registry data is used for:

- health care planning and monitoring
- surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- patient care
- quality assurance
- reporting to the Canadian Cancer Registry, the North American Association of Central Cancer Registries and the International Association of Cancer Registries

Information sources include:

- provincial cytology and pathology departments
- admission/separation data from the provincial hospital abstracting system
- Vital Statistics
- letters and "Report of Malignant Neoplasm Forms" from physicians and other health care providers
- hospital health records
- correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in those jurisdictions

Incidence data

Incidence refers to the number of new cases of cancer diagnosed in Manitoba every year. Cancer cases referenced were diagnosed in the 2013 calendar year. Incidence is also provided by stage of disease at diagnosis.

The Manitoba Cancer Registry uses disease site groupings according to the International Classification of Diseases for Oncology Third Edition (ICD-O3), based on Surveillance Epidemiology and End Results (SEER) Groups. See Appendix 1 for the primary site groupings used for incidence.

Mortality data

Mortality information refers to Manitobans who died of cancer in the 2013 calendar year, however, those patients may not have been diagnosed in 2013. The Vital Statistics Agency of Manitoba reported cancer as the leading cause of death in the province. In 2013, there were 2,673 deaths due to invasive cancer (age standardized rate – 207.3 per 100,000).¹ The totals in the summary on page 13 include all cancer deaths occurring in Manitoba.

Rates

Incidence counts and rates are presented in this report. Annual age-standardized rates are per 100,000 population and allow for comparison of cancer rates in different regions with different age structures. Rates are age-standardized (using the direct method) to the 2001 Manitoba population.

Staging data

The Manitoba Cancer Registry implemented stage data collection for all cases of cancer (excluding non-melanoma skin) diagnosed January 1, 2004 and forward. This data is consistent with the AJCC Cancer Staging Manual, 7th edition.

In this report, stage data is shown for all disease site groups with a cancer incidence of 45 cases per year or more and is represented using pie charts. Stage information, along with frequency of incidence for each of these sites, can also be found in table format on page 10.

Population data

Data are based on Manitoba estimates provided by Manitoba Health, Healthy Living and Seniors.

Additional statistical information is available upon request. Please contact the Manitoba Cancer Registry at:

1-877-787-1272 (toll-free), or
CCMBepireg@cancer.mb.ca

Manitoba's Cancer Profile

Facts & Figures

Manitoba's cancer profile

Cancer is a significant health issue. In 2013, **11,323** Manitobans were diagnosed with cancer:

- **6,290** invasive cancers
- **4,644** in situ (confined to the area of origin)
- **271** unspecified cancers
- **118** benign brain and CNS (central nervous system)

In this same year, **2,673** people died from the disease.

The number of cancer cases in Manitoba is influenced by three factors:

- the age of the population
- the size of the population
- risk factors such as unhealthy living (including smoking, poor diet, inactivity, sun exposure), some environmental carcinogens, genetic predisposition and not being screened.

Most Common Cancer Diagnoses, 2013


Incidence

Male		Female		Total	
SITE	CASES	SITE	CASES	SITE	CASES
Prostate	630	Breast	856	Lung & bronchus	879
Colorectal	446	Lung & bronchus	437	Breast	860
Lung & bronchus	442	Colorectal	384	Colorectal	830
Non-Hodgkin lymphoma	166	Corpus uteri	267	Prostate	630
Kidney	151	Non-Hodgkin lymphoma	134	Non-Hodgkin lymphoma	300
Melanoma of the skin	120	Thyroid	107	Corpus uteri	267
Bladder	100	Melanoma of the skin	102	Kidney	226
Pancreas	85	Pancreas	96	Melanoma of the skin	222
Stomach	79	Ovary	96	Pancreas	181
Chronic lymphocytic leukemia	59	Kidney	75	Thyroid	151
Brain	50	Cervix uteri	46	Bladder	139


Cancer Incidence by Site

Invasive cancers only


Cancer Incidence by Site, Male



Cancer Incidence by Site, Female




Cancer Incidence by Site, Total



Manitoba Cancer Rates by Regional Health Authority


2013 All Invasive Cancers Female Incidence

Age-standardized rate per 100,000
 Standard population: Manitoba 2001
 Out of province residents excluded



2013 All Invasive Cancers Male Incidence

Age-standardized rate per 100,000
 Standard population: Manitoba 2001
 Out of province residents excluded



Cancer Incidence - Cases and Rates in Manitoba by Site, 2013

CANCER SITE		00-29			30-39			40-49			50-59			60-69			70-79			80+			Total Count			*ASIR		
		M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
Buccal cavity & pharynx	Lip	0	0	0	1	0	1	1	2	3	6	1	7	10	8	18	15	4	19	15	8	23	48	23	71	7.86	2.92	5.06
	Tongue	0	0	0	1	0	1	2	1	3	10	4	14	11	1	12	4	4	8	2	0	2	30	10	40	4.20	1.44	2.76
	Major salivary gland	0	0	0	1	0	1	0	1	1	0	1	1	2	0	2	2	0	2	1	0	1	6	2	8	0.96	0.31	0.60
	Floor of mouth	0	0	0	0	0	0	0	1	1	1	2	3	1	0	1	4	2	6	1	1	2	7	6	13	1.16	0.86	0.99
	Gum & other mouth	0	0	0	1	0	1	0	1	1	0	1	1	1	7	8	0	1	1	1	2	3	3	12	15	0.48	1.48	1.00
	Nasopharynx	0	0	0	1	0	1	0	1	1	1	1	2	2	0	2	1	0	1	0	1	1	5	3	8	0.72	0.42	0.57
	Oropharynx	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	1	0	0	0	2	0	2	0.36	0.00	0.17
	Hypopharynx	0	0	0	0	0	0	1	0	1	1	0	1	3	1	4	2	0	2	1	0	1	8	1	9	1.21	0.11	0.62
	Other buccal cavity & pharynx	0	0	0	2	0	2	3	0	3	7	3	10	4	2	6	0	4	4	0	0	0	16	9	25	2.24	1.24	1.76
Digestive	Esophagus	0	0	0	0	0	0	0	0	0	8	4	12	16	6	22	9	3	12	9	3	12	42	16	58	6.24	2.00	3.89
	Stomach	1	0	1	3	2	5	9	1	10	15	8	23	20	5	25	21	8	29	10	10	20	79	34	113	12.27	4.49	8.18
	Small intestine	0	1	1	1	1	2	2	0	2	5	4	9	7	4	11	2	4	6	4	2	6	21	16	37	3.11	2.16	2.57
	Colon excluding rectum	1	6	7	5	6	11	18	10	28	38	25	63	65	58	123	71	78	149	58	99	157	256	282	538	40.63	36.95	38.76
	Rectum & rectosigmoid	2	0	2	3	1	4	9	8	17	42	22	64	52	28	80	50	28	78	32	15	47	190	102	292	29.05	13.7	20.62
	Anus	0	0	0	1	1	2	0	0	0	3	5	8	1	3	4	3	2	5	0	3	3	8	14	22	1.22	1.80	1.55
	Liver	0	0	0	1	0	1	2	1	3	12	3	15	13	4	17	10	8	18	6	4	10	44	20	64	6.54	2.73	4.52
	Gallbladder	0	0	0	1	0	1	0	1	1	1	0	1	3	4	7	1	8	9	0	6	6	6	19	25	0.84	2.57	1.83
	Pancreas	0	1	1	1	1	2	4	0	4	11	12	23	23	30	53	25	26	51	21	26	47	85	96	181	13.52	12.27	12.75
	Other digestive system	0	1	1	1	0	1	1	2	3	2	4	6	6	7	13	9	5	14	5	11	16	24	30	54	3.9	3.84	3.88
Respiratory	Larynx	0	0	0	0	0	0	1	0	1	6	0	6	15	2	17	4	0	4	1	1	2	27	3	30	3.62	0.34	1.93
	Lung & bronchus	0	0	0	1	2	3	8	8	16	63	70	133	118	115	233	161	147	308	91	95	186	442	437	879	70.02	57.6	62.72
	Other respiratory system	1	1	2	0	0	0	0	0	0	1	1	2	0	1	1	2	1	3	1	0	1	5	4	9	0.84	0.56	0.67
Other	Bones & joints	4	5	9	1	0	1	1	0	1	1	1	2	0	1	1	0	1	1	0	1	1	8	8	16	1.30	1.22	1.24
	Soft tissue (Including heart)	3	2	5	2	2	4	2	1	3	5	4	9	5	0	5	5	4	9	3	3	6	25	16	41	3.88	2.33	3.06
	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	2	0	0	0	3	0	3	0.48	0.00	0.23
	Mesothelioma	0	0	0	0	0	0	2	0	2	0	1	1	8	1	9	8	0	8	2	2	4	20	4	24	3.14	0.46	1.72
	Melanoma of the skin	2	3	5	3	7	10	15	14	29	16	26	42	27	20	47	30	17	47	27	15	42	120	102	222	19.31	14.17	16.18
	Breast	0	2	2	0	18	18	0	110	110	1	199	200	1	241	242	1	156	157	1	130	131	4	856	860	0.62	115.13	60.77
Female genital	Cervix uteri		4			6			14			10			5			5			2			46			7.08	
	Corpus uteri		0			6			24			69			94			57			17			267			35.73	
	Uterus, NOS		1			0			1			2			0			0			0			4			0.60	
	Ovary		6			3			15			27			21			9			15			96			13.12	
	Other female genital system		1			1			3			8			10			10			11			44			5.84	


CANCER SITE		00-29			30-39			40-49			50-59			60-69			70-79			80+			Total Count			*ASIR		
		M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T	M	F	T
Male genital	Prostate	0			1			7			111			233			182			96			630			94.22		
	Testis	11			12			10			1			1			1			0			36			6.04		
	Penis	1			0			1			2			0			5			2			11			1.88		
	Other male genital system	0			0			0			1			0			1			1			3			0.50		
Urinary	Bladder	0	0	0	0	0	0	1	0	1	12	3	15	26	5	31	20	11	31	41	20	61	100	39	139	16.17	4.91	9.73
	Kidney	2	3	5	3	3	6	13	9	22	31	13	44	62	23	85	25	13	38	15	11	26	151	75	226	21.78	10.18	15.64
	Ureter	0	0	0	0	0	0	0	0	0	1	0	1	1	1	2	0	0	0	0	5	5	2	6	8	0.24	0.67	0.53
	Other urinary system	0	0	0	0	0	0	0	0	0	1	1	2	1	0	1	2	1	3	2	0	2	6	2	8	0.99	0.29	0.58
Brain & other CNS	Eye	0	0	0	0	1	1	1	0	1	2	1	3	0	0	0	0	1	1	0	1	1	3	4	7	0.43	0.57	0.52
	Brain	5	10	15	3	4	7	7	1	8	11	5	16	13	12	25	8	3	11	3	4	7	50	39	89	7.51	5.43	6.41
	Other CNS	0	1	1	0	2	2	1	0	1	1	1	2	0	1	1	0	0	0	0	0	0	2	5	7	0.31	0.75	0.53
Endocrine	Thyroid	2	7	9	5	17	22	7	27	34	16	27	43	9	15	24	3	7	10	2	7	9	44	107	151	6.45	15.99	11.28
	Other endocrine	4	0	4	0	0	0	0	0	0	0	1	1	0	3	3	0	1	1	0	0	0	4	5	9	0.63	0.63	0.64
Lymphoma	Hodgkin lymphoma	6	4	10	6	0	6	4	2	6	0	0	0	5	0	5	3	1	4	0	2	2	24	9	33	3.84	1.40	2.63
	Non-Hodgkin lymphoma	4	1	5	2	5	7	9	7	16	34	19	53	44	27	71	42	38	80	31	37	68	166	134	300	25.59	17.91	21.45
	Multiple myeloma	0	0	0	0	0	0	2	1	3	5	6	11	12	14	26	22	11	33	7	11	18	48	43	91	7.74	5.50	6.53
Leukemias	Acute lymphocytic leukemia	1	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0.16	0.16	0.16
	Chronic lymphocytic leukemia	0	0	0	0	0	0	1	2	3	10	2	12	20	11	31	15	9	24	13	7	20	59	31	90	8.99	4.07	6.26
	Acute myeloid leukemia	2	2	4	4	1	5	2	1	3	4	2	6	2	1	3	14	4	18	11	4	15	39	15	54	6.75	2.13	4.15
	Chronic myeloid leukemia	1	1	2	0	0	0	3	1	4	2	1	3	4	2	6	2	1	3	3	3	6	15	9	24	2.35	1.19	1.73
	Other leukemias	8	6	14	1	0	1	4	0	4	6	1	7	2	2	4	3	2	5	6	1	7	30	12	42	4.83	1.76	3.16
	Other, ill defined & unknown	1	0	1	0	3	3	8	5	13	11	12	23	27	18	45	26	33	59	32	38	70	105	109	214	16.96	14.44	15.47
TOTAL - ALL INVASIVE		62	70	132	68	93	161	163	276	439	518	613	1131	877	814	1691	817	728	1545	558	633	1191	3063	3227	6290	474.07	433.43	447.81
In situ	Other skin & in situ	9	7	16	20	40	60	102	98	200	238	242	480	470	323	793	514	369	883	521	466	987	1874	1545	3419	300.95	203.45	244.69
	Breast in situ	0	0	0	0	3	3	0	12	12	0	29	29	0	31	31	0	31	31	0	7	7	0	113	113	0.00	15.58	8.09
	Cervix in situ		201			128			55			22			13			3			0			422			69.74	
	Prostate in situ	0			0			0			5			13			11			1			30			4.35		
	Bladder in situ	1	0	1	0	1	1	4	3	7	16	5	21	37	8	45	47	11	58	29	14	43	134	42	176	21.31	5.56	12.65
	Other in situ (Excl. Breast, Skin, Cervix, Prostate, Bladder)	1	2	3	3	4	7	14	13	27	59	35	94	82	48	130	87	57	144	46	33	79	292	192	484	44.86	25.97	34.48
TOTAL - INVASIVE & IN SITU		73	280	353	91	269	360	283	457	740	836	946	1782	1479	1237	2716	1476	1199	2675	1155	1153	2308	5393	5541	10934	845.54	753.73	784.37
Neoplasms (Uncertain & unspecified, excluding brain)	Brain uncertain & unspecified	1	6	7	1	2	3	1	0	1	2	2	4	0	3	3	1	1	2	1	0	1	7	14	21	1.14	2.08	1.58
	Neoplasms (Uncertain & unspecified, excluding brain)	4	12	16	6	10	16	6	20	26	15	31	46	13	28	41	27	27	54	27	24	51	98	152	250	16.21	21.37	18.45
	Brain & nervous system benign	2	6	8	1	3	4	13	15	28	6	14	20	13	5	18	7	12	19	7	14	21	49	69	118	7.71	10.02	8.90
ALL CANCERS		80	304	384	99	284	383	303	492	795	859	993	1852	1505	1273	2778	1511	1239	2750	1190	1191	2381	5547	5776	11323	870.6	787.21	813.3

*Age-standardized incidence rate per 100,000
Standard population: Manitoba 2001

Staging on sites with more than 45 cases*

Lip

	Frequency	Percent
Stage I	54	76.1
Stage II	6	8.5
Stage III	0	0.0
Stage IV	0	0.0
Unknown	11	15.5
Total	71	100




Esophagus

	Frequency	Percent
Stage I	12	20.7
Stage II	15	25.9
Stage III	11	19.0
Stage IV	16	27.6
Unknown	4	6.9
Total	58	100



Stomach

	Frequency	Percent
Stage I	16	14.2
Stage II	17	15.0
Stage III	22	19.5
Stage IV	48	42.5
Unknown	10	8.9
Total	113	100




Colon excluding rectum

	Frequency	Percent
Stage I	119	22.2
Stage II	168	31.3
Stage III	137	25.5
Stage IV	97	18.1
Unknown	16	3.0
Total	537	100




Rectum & rectosigmoid

	Frequency	Percent
Stage I	71	24.4
Stage II	47	16.2
Stage III	99	34.0
Stage IV	66	22.7
Unknown	8	2.8
Total	291	100




Liver

	Frequency	Percent
Stage I	15	23.4
Stage II	9	14.1
Stage III	14	21.9
Stage IV	10	15.6
Unknown	16	25.0
Total	64	100




Pancreas

	Frequency	Percent
Stage I	28	15.5
Stage II	47	26.0
Stage III	11	6.1
Stage IV	85	47.0
Unknown	10	5.5
Total	181	100




Other digestive system

	Frequency	Percent
Stage I	10	18.5
Stage II	8	14.8
Stage III	8	14.8
Stage IV	15	27.8
Unknown	13	24.1
Total	54	100




Lung & bronchus

	Frequency	Percent
Stage I	229	26.1
Stage II	70	8.0
Stage III	176	20.0
Stage IV	398	45.3
Unknown	6	0.7
Occult	0	0.0
Total	879	100




Melanoma of the skin

	Frequency	Percent
Stage I	164	73.9
Stage II	31	14.0
Stage III	18	8.1
Stage IV	8	3.6
Unknown	1	0.5
Total	222	100.0




Breast

	Frequency	Percent
Stage I	382	44.4
Stage II	309	35.9
Stage III	110	12.8
Stage IV	55	6.4
Unknown	4	0.5
Total	860	100




Cervix uteri

	Frequency	Percent
Stage I	20	43.5
Stage II	13	28.3
Stage III	8	17.4
Stage IV	5	10.9
Unknown	0	0.0
Total	46	100




Corpus uteri

	Frequency	Percent
Stage I	192	71.9
Stage II	29	10.9
Stage III	29	10.9
Stage IV	12	4.5
Unknown	5	1.9
Total	267	100




Ovary

	Frequency	Percent
Stage I	26	27.1
Stage II	11	11.5
Stage III	47	49.0
Stage IV	11	11.5
Unknown	1	1.0
Total	96	100




Prostate

	Frequency	Percent
Stage I	101	16.0
Stage II	351	55.7
Stage III	77	12.2
Stage IV	97	15.4
Unknown	4	0.6
Total	630	100




Bladder

	Frequency	Percent
Stage I	65	46.8
Stage II	35	25.2
Stage III	9	6.5
Stage IV	26	18.7
Unknown	4	2.9
Total	139	100




Kidney

	Frequency	Percent
Stage I	127	56.2
Stage II	8	3.5
Stage III	48	21.2
Stage IV	37	16.4
Unknown	6	2.7
Total	226	100




Thyroid

	Frequency	Percent
Stage I	96	63.6
Stage II	13	8.6
Stage III	21	13.9
Stage IV	20	13.3
Unknown	1	0.7
Total	151	100



Non-Hodgkin lymphoma

	Frequency	Percent
Stage I	64	21.5
Stage II	57	19.1
Stage III	62	20.8
Stage IV	111	37.3
Unknown	4	1.3
Total	298	100



**In keeping with international coding conventions, all invasive brain tumours, multiple myeloma and leukemia are considered unstageable using the collaborative staging system utilized by all population-based North American Cancer Registries.*

Deaths by Underlying Cause in Manitoba¹

(Rate per 100,000)

CAUSES OF DEATH	2013			2012			2011		
	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population	AMOUNT	Rate per MB Health Population	Rate per Statistics Canada Population
Accidents (V01-X59, Y85-Y86)	515	39.9	40.8	533	41.9	42.1	539	43.1	43.1
Cancer (C00-C97)	2,673	207.3	212.0	2704	212.7	213.4	2696	215.6	215.6
Cerebrovascular Disease (I60-I69)	608	47.2	48.2	612	48.1	48.3	604	48.3	48.3
Diabetes (E10-E14)	339	26.3	26.9	323	25.4	25.5	407	32.5	32.5
Diseases of the heart (I00-I09, I11, I13, I20-I25, I26-I51)	2076	161.0	164.6	2105	165.6	166.1	2137	170.9	170.9
Pneumonia (J12-J18)	220	17.1	17.4	235	18.5	18.5	219	17.5	17.5
Suicide (X60-X84, Y890)	158	12.3	12.5	165	13.0	13.0	141	11.3	11.3

Reference

¹Vital Statistics Agency, 2013/14 Annual Report. Government of Manitoba; 2015. [cited May 25, 2015]. http://vitalstats.gov.mb.ca/pdf/2014_vs_annual_report_en.pdf

Research

2013 Publications

This is only a sample of publications that have used Manitoba Cancer Registry Data. For a complete listing, please visit www.cancercare.mb.ca and click on Epidemiology and Cancer Registry under the Research tab. Articles with names in bold are authored by department staff.

Ahmed N, Owen TE, Rubinger M, Williams G, **Nugent Z**, Ahmed S, et al. Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. *PLoS One* 2013;8:e65156.

Beiggi S, Johnston JB, Seftel MD, Pitz MW, Kumar R, Banerji V, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. *Br J Cancer* 2013;109:1287-90.

Brisson M, Drolet M, Boily MC, Malagon T, Franco EL, Laprise J, et al. Response. *J Natl Cancer Inst* 2013;105:664-5.

Brisson M, Laprise JF, Drolet M, Van d, V, Franco EL, **Kliewer EV**, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. *Vaccine* 2013;31:3863-71.

Decker KM, Turner D, Demers AA, Martens PJ, **Lambert P**, Chateau D. Evaluating the effectiveness of cervical cancer screening invitation letters. *J Womens Health (Larchmt)* 2013;22:687-93.

Helewa RM, **Turner D**, Wirtzfeld D, Park J, Hochman D, Czaykowski P, et al. Does geography influence the treatment and outcomes of colorectal cancer? A population-based analysis. *World J Surg Oncol* 2013;11:140.

Helewa RM, **Turner D**, Wirtzfeld D, Park J, Hochman DJ, Czaykowski P, et al. Geographical disparities of rectal cancer local recurrence and outcomes: a population-based analysis. *Dis Colon Rectum* 2013;56:850-8.

Helewa RM, **Turner D**, Park J, Wirtzfeld D, Czaykowski P, Hochman D, et al. Longer waiting times for patients undergoing colorectal cancer surgery are not associated with decreased survival. *J Surg Oncol* 2013;108:378-84.

Holmes S, **Griffith EJ, Musto G**, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. *Cancer Epidemiol* 2013;37:881-5.

Kliewer EV, Mahmud SM, Demers AA, **Lambert P**. Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. *Vaccine* 2013;32:33-8.

Leddin D, Enns R, Hilsden R, Fallone CA, Rabeneck L, Sadowski DC, et al. Colorectal cancer surveillance after index colonoscopy: guidance from the Canadian Association of Gastroenterology. *Can J Gastroenterol* 2013;27:224-8.

Liu HW, Khan R, D'Ambrosi R, Krobutschek K, **Nugent Z**, Lau H. The influence of target and patient characteristics on the volume obtained from cone beam CT in lung stereotactic body radiation therapy. *Radiother Oncol* 2013.

Lothar SA, Harding GA, **Musto G**, Navaratnam S, Pitz MW. Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. *Horm Cancer* 2013;4:270-6.

Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, et al. Stage at diagnosis and colorectal cancer survival

in six high-income countries: a population-based study of patients diagnosed during 2000-2007. *Acta Oncol* 2013;52:919-32.

Mosavi-Jarrahi A, **Kliwer EV**. Cervical cancer incidence trends in Canada: a 30-year population-based analysis. *J Obstet Gynaecol Can* 2013;35:620-6.

Mou B, Cooke AL, **Xue L**. Utilization of preoperative radiation therapy in the management of rectal cancer: A population-based analysis. *Pract Radiat Oncol* 2013;3:e121-e126.

Murnaghan D, Morrison W, **Griffith EJ**, Bell BL, Duffley LA, McGarry K, et al. Knowledge exchange systems for youth health and chronic disease prevention: a tri-provincial case study. *Chronic Dis Inj Can* 2013;33:257-66.

Pathak KA, Mazurat A, **Lambert P**, Klonisch T, Nason RW. Prognostic nomograms to predict oncological outcome of thyroid cancers. *J Clin Endocrinol Metab* 2013;98:4768-75.

Peterson DJ, Ahmed N, Rivest R, Bashir B, Ahmed S, Demeter S, et al. A Prospective Study To Determine Inter-Observer Variability of Gross Tumor Volume with [18F] Fludeoxyglucose - PET/CT Compared to CT Alone in Stage III Non-Small Cell Lung Cancer Using Three-Dimensional Analysis. *Cureus* 2013;5(7): e130.

Pitz MW, **Musto G**, Navaratnam S. Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. *Can Respir J* 2013;20:30-4.

Pruthi DK, **Nugent Z**, Czaykowski P, Demers AA. Urothelial cancer and the diagnosis of subsequent malignancies. *Can Urol Assoc J* 2013;7:E57-E64.

Schultz AS, **Nowatzki J**, Ronson G. Effects of household socialization on youth susceptibility to smoke: differences between youth age groups and trends over time. *Am J Public Health* 2013;103:e39-e42.

Shafer LA, Jeffrey I, Elias B, Shearer B, Canfell K, **Kliwer E**. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. *Vaccine* 2013;31:4848-55.

Singh H, **Nugent Z**, Demers A, Czaykowski PM, Mahmud SM. Risk of colorectal cancer after diagnosis of endometrial cancer: a population-based study. *J Clin Oncol* 2013;31:2010-5.

Skrabek P, **Turner D**, Seftel M. Epidemiology of non-Hodgkin lymphoma. *Transfus Apher Sci* 2013;49:133-8.

Thosani N, Thosani SN, Kumar S, **Nugent Z**, Jimenez C, Singh H, et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. *J Clin Oncol* 2013;31:623-30.

Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. *Thorax* 2013.

Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *Br J Cancer* 2013.

Yan Y, Penner CC, Skliris GP, Cooper C, **Nugent Z**, Blanchard A, et al. Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors. *J Cancer Res Clin Oncol* 2013;139:1637-47.

Appendix 1

INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY 3rd Edition

PRIMARY SITE	SITE/ CELL TYPE	PRIMARY SITE	SITE/ CELL TYPE
Buccal cavity and pharynx	C00:C14	Male genital system	C60:C63
Lip	C000:C009	Prostate	C619
Tongue	C019:C029	Testis	C620:C629
Major salivary gland	C079:C089	Penis	C600:C609
Floor of mouth	C040:C049	Other male genital system	C630:C639
Gum & other mouth	C030:C039, C050:C059, C060:C069	Urinary system	C64:C68
Nasopharynx	C110:C119	Bladder (incl. in situ)	C670:C679
Oropharynx	C100:C109	Kidney and renal pelvis	C649, C659
Hypopharynx	C129, C130:C139	Ureter	C669
Other buccal cavity & pharynx	C090:C099, C140, C142:C148	Other urinary system	C680:C689
Digestive system	C15:C26	Eye	C690:C699
Esophagus	C150:C159	Brain & other nervous system	C70:C72
Stomach	C160:C169	Brain	C710:C719
Small intestine	C170:C179	Other nervous system	C710:C719 (type 953), C700:C709
Colon excluding rectum	C180:C189, C260		C720:C729
Rectum & Rectosigmoid	C199, C209	Endocrine	C73:C75
Anus	C210:C212, C218	Thyroid	C739
Liver	C220	Other endocrine	C379, C740:C749, C750:C759
Gallbladder	C239	Lymphomas	C77
Pancreas	C250:C259	Hodgkin disease	types 9650:9667
Other digestive system	C240:C249, C221, C480, C481:C482, C268:C269, C488	Non-Hodgkin lymphoma	types 9590:9596, 9670:9719, 9727:9729, 9597
Respiratory system	C30:C39		type 9823, all sites except C420, C421, C424
Larynx	C320:C329		type 9827, all sites except C420, C421, C424
Lung & bronchus	C340:C349	Multiple myeloma	C421, types 9731:9732, 9734
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399	Leukemias	C42
Bones & joints	C400:C419	Acute lymphocytic	types 9826, 9835:9837
Soft tissue (including heart)	C380, C470:C479, C490:C499	Chronic lymphocytic	C420(type 9823), C421 (type 9823), C421 (type 9823), C424 (type 9823)
Mesothelioma	types 9050:9055	Acute myeloid	types 9840, 9861, 9866, 9867, 9871:9874, 9891, 9895:9897, 9910, 9920, 9865, 9869
Kaposi sarcoma	types 9140	Chronic myeloid	types 9863, 9875, 9876, 9945, 9946
Skin	C44	Other	types 9733, 9742, 9800, 9801, 9805, 9806-9809, 9811-9818, 9820, 9831, 9832:9834, 9860, 9870, 9930, 9931, 9940, 9948, 9963, 9964
Melanomas of the skin	C440:C449 (types 8720:8790)		C420 (type 9827), C421 (type 9827), C424 (type 9827)
Other skin	C440:C449	Other, ill-defined, & unknown	types 9740,9741, 9750:9758, 9760:9769, 9950:9962, 9970:9989
Breast	C500:C509		C760:C768, (types 8000:9589)
Female genital system	C51:C58		C809 (types 8000:9589)
Cervix uteri	C530:C539		C420:C424 (types 8000:9589)
Corpus uteri	C540:C549		C770:C779 (types 8000:9589)
Uterus, NOS	C559		
Ovary	C569		
Other female genital system	C529, C510:C519, C570:C589		

2015 Department of Epidemiology and Cancer Registry Staff

Donna Turner, PhD

PROVINCIAL DIRECTOR, POPULATION ONCOLOGY
INTERIM MANAGER, EPIDEMIOLOGY UNIT

Gail Noonan, CTR

MANAGER,
MANITOBA CANCER REGISTRY

CANCER REGISTRARS

Elena Avila, HIT

Jennifer Cadger, HIT

Danielle Chalmers, CHIM

Angela Deneka, HIT

Sheila Fukumura, CTR
SENIOR CANCER REGISTRAR

Sara Gray, CHIM

Pat Hagan, HIT

Terri-Lee Handel, CTR

Coreen Hildebrand, CTR
SENIOR QUALITY CONTROL COORDINATOR

Jo-Anne Janzen, CHIM, CTR
SENIOR EDUCATION COORDINATOR

Sharon Lawrence, HIT

Loriann Love, HIT

Joanna Panganiban, CHIM

Margaret Schroeder, HIM

Melissa Scott, CHIM

EPIDEMIOLOGISTS

Oliver Bucher, MSc

Kathleen Decker, PhD

Tannis Erickson, MSc

Donna Turner, PhD

HEALTH OUTCOMES ANALYSTS

Pascal Lambert, MSc

Charlene Muzyka, MSc

PROGRAMMER ANALYSTS

Katie Galloway, MSc

Huimin Lu, MSc

Grace Musto, BSc

Mary Natividad, BSc

Alexander Sachs, BComm

Emma Shu, MSc

Lin Xue, MSc

STUDY COORDINATORS

Elizabeth Harland, MA

Kate McGarry, MSc, MPA

CANCER RESEARCH & EVALUATION COORDINATOR

Carrie O'Conaill, MPH

PROJECT MANAGER

Cheryl Clague, CHIM

ADMINISTRATIVE ASSISTANT

Karen Carson-Walton

CONTACT DETAILS

Room ON2114
675 McDermot Ave.
Winnipeg, MB R3E 0V9

Main line: (204) 787-2174
Email: CCMBepireg@cancercare.mb.ca

TO CITE THIS REPORT

Department of Epidemiology and Cancer Registry, CancerCare Manitoba.
“Cancer in Manitoba, 2013 Annual Statistical Report.”

Find the Department of Epidemiology and Cancer Registry and data request guidelines online under the Research tab at www.cancercare.mb.ca

